A prognostic model for HIV seroconversion among injection drug users as a tool for stratification in clinical trials

被引:20
作者
Boileau, C
Bruneau, J
Al-Nachawati, H
Lamothe, F
Vincelette, J
机构
[1] Univ Montreal, Ctr Hosp, Dept Social & Prevent Med, Montreal, PQ, Canada
[2] Univ Montreal, Ctr Hosp, Res Ctr, Montreal, PQ, Canada
[3] Univ Montreal, Dept Family Med, Montreal, PQ, Canada
[4] Univ Montreal, Dept Immunol & Microbiol, Montreal, PQ, Canada
关键词
prognostic model; risk score; survival study; HIV behavioral risk factors; injection drug use;
D O I
10.1097/01.qai.0000153424.56379.61
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: The main goal of this study was to construct a prognostic model for HIV seroconversion among injection drug users (IDUs) using easy-to-measure risk indicators. Design: Cox proportional hazards regression modeling was used for risk stratification in a heterogeneous population of IDUs with regards to HIV risk-taking behaviors. Methods: Subjects were recruited in a prospective cohort of IDUs followed between September 1992 and October 2001. A total of 1602 men, seronegative at enrollment with at least 1 follow-up visit, were included in the analyses. Only variables that consistently predict HIV seroconversion in several settings were considered. The final model was used to assign a risk score for each participant. Results: Three risk indicators were included in the risk score to predict HIV seroconversion: unstable housing, average cocaine injections per day, and having shared a syringe with a known HIV-positive partner. Kaplan-Meier survival functions were generated and risk score values stratified in 3 groups. HIV incidence rates per 100 person-years were as follows: 0.91 (95% Cl, 0.55-1.52) for the low-risk group, 3.10 (95% Cl, 2.49-3.84) for the moderate-risk group, and 7.82 (95% Cl, 6.30-9.73) for the high-risk group (log-rank P value < 0.0001). Conclusion: If validated in other settings, this risk score may improve the prediction of outcome and allow more accurate stratification in clinical trials.
引用
收藏
页码:489 / 495
页数:7
相关论文
共 48 条
[31]  
Mistry F P, 1991, Indian J Gastroenterol, V10, P82
[32]   Staging classification of lung cancer - A critical evaluation [J].
Mountain, CF .
CLINICS IN CHEST MEDICINE, 2002, 23 (01) :103-+
[33]   High-risk personal networks and syringe sharing as risk factors for HIV infection among new drug injectors [J].
Neaigus, A ;
Friedman, SR ;
Jose, B ;
Goldstein, MF ;
Curtis, R ;
Ildefonso, G ;
DesJarlais, DC .
JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 1996, 11 (05) :499-509
[34]  
PERRON S, 2002, CAN J INFECT DIS SA, V13
[35]   Simplified risk score models accurately predict the risk of major in-hospital complications following percutaneous coronary intervention [J].
Resnic, FS ;
Ohno-Machado, L ;
Selwyn, A ;
Simon, DI ;
Popma, JJ .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (01) :5-9
[36]   Screening for colon cancer and evaluation of chemoprevention with coxibs [J].
Rex, DK .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2002, 23 (04) :S41-S50
[37]   Explosive spread and high prevalence of HIV infection among injecting drug users in Togliatti City, Russia [J].
Rhodes, T ;
Lowndes, C ;
Judd, A ;
Mikhailova, LA ;
Sarang, A ;
Rylkov, A ;
Tichonov, M ;
Lewis, K ;
Ulyanova, N ;
Alpatova, T ;
Karavashkin, V ;
Khutorskoy, M ;
Hickman, M ;
Parry, JV ;
Renton, A .
AIDS, 2002, 16 (13) :F25-F31
[38]  
Sarkar S., 1993, Bulletin on Narcotics, V45, P91
[39]  
SCHLICHTING P, 1983, HEPATOLOGY, V3, P889
[40]  
Shah Sudeep, 2003, Indian J Gastroenterol, V22, P43